Protagonist Therapeutics (PTGX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

PTGX Stock Forecast

Protagonist Therapeutics stock forecast is as follows: an average price target of $57.33 (represents a 44.99% upside from PTGX’s last price of $39.54) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

PTGX Price Target

The average price target for Protagonist Therapeutics (PTGX) is $57.33 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $62.00 to $50.00. This represents a potential 44.99% upside from PTGX's last price of $39.54.

PTGX Analyst Ratings

Buy

According to 6 Wall Street analysts, Protagonist Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PTGX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Protagonist Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 05, 2024	Etzer Darout	BMO Capital	$62.00	$41.68	48.75%	56.80%
Nov 22, 2024	Srikripa Devarakonda	Truist Financial	$60.00	$46.46	29.14%	51.75%
Sep 12, 2024	Douglas Tsao	H.C. Wainwright	$50.00	$45.08	10.91%	26.45%
Jun 17, 2024	Douglas Tsao	H.C. Wainwright	$38.00	$32.86	15.64%	-3.89%

The latest Protagonist Therapeutics stock forecast, released on Dec 05, 2024 by Etzer Darout from BMO Capital, set a price target of $62.00, which represents a 48.75% increase from the stock price at the time of the forecast ($41.68), and a 56.80% increase from PTGX last price ($39.54).

Protagonist Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	2	2	4
Avg Price Target	$61.00	$61.00	$52.50
Last Closing Price	$39.54	$39.54	$39.54
Upside/Downside	54.27%	54.27%	32.78%

In the current month, the average price target of Protagonist Therapeutics stock is $61.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 54.27% increase as opposed to Protagonist Therapeutics's last price of $39.54. This month's average price target is down 0.00% compared to last quarter, and up 16.19% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 05, 2024	BMO Capital		Outperform	Initialise
Oct 14, 2024	Cowen & Co.	Buy	Buy	Hold
Sep 24, 2024	Cowen & Co.		Buy	Initialise
Sep 12, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 07, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 24, 2024	BTIG	Buy	Buy	Hold
Jun 17, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 06, 2023	JMP Securities	Market Outperform	Market Outperform	Hold
May 17, 2022	Piper Sandler	Overweight	Overweight	Hold

Protagonist Therapeutics's last stock rating was published by BMO Capital on Dec 05, 2024. The company Initialise its PTGX rating from "null" to "Outperform".

Protagonist Therapeutics Financial Forecast

Protagonist Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
Revenue	-	-	-	-	-	-	-	-	-	-	-	$859.00K	$25.72M	$8.62M	$10.29M	$2.27M	$6.19M	$5.65M	$13.11M	$6.22M	$3.65M	$2.72M	$4.14M	$-8.19M	$1.56M	$10.78M
Avg Forecast	$33.29M	$13.20M	$16.70M	$47.72M	$49.46M	$3.11M	$3.14M	$262.50M	$60.00M	$2.00M	$3.33M	$460.00K	$21.18M	$5.07M	$1.74M	$5.17M	$1.50M	$2.70M	$2.87M	$2.95M	$1.48M	$4.23M	$4.83M	$11.20M	$4.89M	$8.68M
High Forecast	$84.71M	$33.59M	$42.50M	$121.44M	$110.66M	$7.92M	$8.00M	$668.06M	$152.70M	$5.09M	$8.48M	$460.00K	$21.18M	$5.07M	$1.74M	$5.17M	$1.50M	$2.70M	$2.87M	$2.95M	$1.48M	$4.23M	$4.83M	$11.20M	$4.89M	$10.42M
Low Forecast	$2.09M	$830.20K	$1.05M	$3.00M	$4.60M	$195.76K	$197.60K	$16.51M	$3.77M	$125.79K	$209.65K	$460.00K	$21.18M	$5.07M	$1.74M	$5.17M	$1.50M	$2.70M	$2.87M	$2.95M	$1.48M	$4.23M	$4.83M	$11.20M	$4.89M	$6.95M
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	5	4	5	4	4	3	4	3	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.87%	1.21%	1.70%	5.90%	0.44%	4.13%	2.09%	4.57%	2.11%	2.46%	0.64%	0.86%	-0.73%	0.32%	1.24%

Protagonist Therapeutics's average Quarter revenue forecast for Dec 22 based on 1 analysts is $3.33M, with a low forecast of $209.65K, and a high forecast of $8.48M. PTGX's average Quarter revenue forecast represents a 288.05% increase compared to the company's last Quarter revenue of $859.00K (Jun 22).

Protagonist Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	5	4	5	4	4	3	4	3	8
EBITDA	-	-	-	-	-	-	-	-	-	$-36.02M	$-36.52M	$-40.60M	$-20.28M	$-36.09M	$-33.10M	$-30.21M	$-23.37M	$-18.13M	$-7.12M	$-17.44M	$-19.00M	$-15.83M	$-15.87M	$-30.18M	$-13.33M	$-7.58M
Avg Forecast	$-33.29M	$-13.20M	$-16.70M	$-47.72M	$-49.46M	$-3.11M	$-3.14M	$-22.95M	$-60.00M	$-24.55M	$-34.17M	$-460.00K	$-26.26M	$-5.07M	$-1.74M	$-5.17M	$-24.60M	$-2.70M	$-2.87M	$-2.95M	$-18.17M	$-4.23M	$-4.83M	$-11.20M	$-13.56M	$-5.75M
High Forecast	$-2.09M	$-830.20K	$-1.05M	$-3.00M	$-4.60M	$-195.76K	$-197.60K	$-18.36M	$-3.77M	$-19.64M	$-27.34M	$-460.00K	$-21.00M	$-5.07M	$-1.74M	$-5.17M	$-19.68M	$-2.70M	$-2.87M	$-2.95M	$-14.54M	$-4.23M	$-4.83M	$-11.20M	$-10.85M	$-4.60M
Low Forecast	$-84.71M	$-33.59M	$-42.50M	$-121.44M	$-110.66M	$-7.92M	$-8.00M	$-27.54M	$-152.70M	$-29.46M	$-41.01M	$-460.00K	$-31.51M	$-5.07M	$-1.74M	$-5.17M	$-29.53M	$-2.70M	$-2.87M	$-2.95M	$-21.81M	$-4.23M	$-4.83M	$-11.20M	$-16.27M	$-6.90M
Surprise %	-	-	-	-	-	-	-	-	-	1.47%	1.07%	88.26%	0.77%	7.12%	18.99%	5.84%	0.95%	6.71%	2.48%	5.91%	1.05%	3.74%	3.29%	2.69%	0.98%	1.32%

undefined analysts predict PTGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Protagonist Therapeutics's previous annual EBITDA (undefined) of $NaN.

Protagonist Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	5	4	5	4	4	3	4	3	8
Net Income	-	-	-	-	-	-	-	-	-	$-31.43M	$-31.29M	$-40.63M	$-20.75M	$-36.91M	$-33.80M	$-30.84M	$-24.00M	$-18.89M	$-7.76M	$-19.42M	$-20.08M	$-17.50M	$-16.41M	$-29.17M	$-14.10M	$-7.66M
Avg Forecast	$-26.87M	$-35.21M	$-32.87M	$6.11M	$8.24M	$-35.67M	$-36.78M	$-24.11M	$3.31M	$-25.78M	$-34.95M	$-57.34M	$-27.57M	$-47.94M	$-41.07M	$-33.44M	$-25.26M	$-29.30M	$-37.55M	$-34.64M	$-19.21M	$-39.73M	$-43.32M	$-17.17M	$-14.34M	$-5.81M
High Forecast	$5.86M	$7.68M	$7.17M	$34.49M	$848.45M	$7.78M	$8.03M	$-19.29M	$14.28M	$-20.63M	$-27.96M	$-57.34M	$-22.06M	$-47.94M	$-41.07M	$-33.44M	$-20.21M	$-29.30M	$-37.55M	$-34.64M	$-15.37M	$-39.73M	$-43.32M	$-17.17M	$-11.47M	$-4.65M
Low Forecast	$-80.84M	$-105.92M	$-98.90M	$-10.96M	$-469.53M	$-107.31M	$-110.64M	$-28.93M	$-7.66M	$-30.94M	$-41.94M	$-57.34M	$-33.09M	$-47.94M	$-41.07M	$-33.44M	$-30.31M	$-29.30M	$-37.55M	$-34.64M	$-23.05M	$-39.73M	$-43.32M	$-17.17M	$-17.21M	$-6.97M
Surprise %	-	-	-	-	-	-	-	-	-	1.22%	0.90%	0.71%	0.75%	0.77%	0.82%	0.92%	0.95%	0.64%	0.21%	0.56%	1.05%	0.44%	0.38%	1.70%	0.98%	1.32%

Protagonist Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PTGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Protagonist Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	5	4	5	4	4	3	4	3	8
SG&A	-	-	-	-	-	-	-	-	-	$8.61M	$6.63M	$7.69M	$10.52M	$7.26M	$7.26M	$6.71M	$5.96M	$4.99M	$4.89M	$4.18M	$4.58M	$4.11M	$4.01M	$3.86M	$3.76M	$3.64M
Avg Forecast	$476.48M	$188.96M	$239.06M	$683.08M	$708.04M	$44.56M	$44.97M	$12.11M	$858.90M	$28.63M	$47.72M	$6.58M	$13.85M	$72.60M	$24.95M	$74.03M	$21.47M	$38.65M	$41.04M	$42.23M	$21.19M	$60.52M	$69.09M	$160.33M	$3.83M	$2.76M
High Forecast	$1.21B	$480.89M	$608.40M	$1.74B	$1.58B	$113.39M	$114.46M	$14.53M	$2.19B	$72.86M	$121.44M	$6.58M	$16.62M	$72.60M	$24.95M	$74.03M	$21.47M	$38.65M	$41.04M	$42.23M	$21.19M	$60.52M	$69.09M	$160.33M	$4.59M	$3.32M
Low Forecast	$29.97M	$11.88M	$15.04M	$42.96M	$65.84M	$2.80M	$2.83M	$9.69M	$54.02M	$1.80M	$3.00M	$6.58M	$11.08M	$72.60M	$24.95M	$74.03M	$21.47M	$38.65M	$41.04M	$42.23M	$21.19M	$60.52M	$69.09M	$160.33M	$3.06M	$2.21M
Surprise %	-	-	-	-	-	-	-	-	-	0.30%	0.14%	1.17%	0.76%	0.10%	0.29%	0.09%	0.28%	0.13%	0.12%	0.10%	0.22%	0.07%	0.06%	0.02%	0.98%	1.32%

Protagonist Therapeutics's average Quarter SG&A projection for Dec 23 is $858.90M, based on 3 Wall Street analysts, with a range of $54.02M to $2.19B. The forecast indicates a 9881.39% rise compared to PTGX last annual SG&A of $8.61M (Mar 23).

Protagonist Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	4	6	3	1	1	3	1	1	1	1	1	1	1	1	5	4	5	4	4	3	4	3	8
EPS	-	-	-	-	-	-	-	-	-	$-0.62	$-0.64	$-0.83	$-0.43	$-0.77	$-0.70	$-0.69	$-0.54	$-0.48	$-0.21	$-0.59	$-0.72	$-0.63	$-0.61	$-1.18	$-0.58	$-0.36
Avg Forecast	$-0.43	$-0.57	$-0.53	$0.10	$0.13	$-0.58	$-0.60	$3.37	$0.05	$-0.73	$-0.67	$-0.94	$-0.54	$-0.78	$-0.67	$-0.55	$-0.57	$-0.48	$-0.61	$-0.56	$-0.69	$-0.65	$-0.71	$-0.28	$-0.59	$-0.22
High Forecast	$0.09	$0.12	$0.12	$0.56	$13.74	$0.13	$0.13	$10.13	$0.23	$0.16	$0.15	$-0.94	$-0.54	$-0.78	$-0.67	$-0.55	$-0.57	$-0.48	$-0.61	$-0.56	$-0.69	$-0.65	$-0.71	$-0.28	$-0.59	$-0.18
Low Forecast	$-1.31	$-1.71	$-1.60	$-0.18	$-7.60	$-1.74	$-1.79	$-0.73	$-0.12	$-2.18	$-2.01	$-0.94	$-0.54	$-0.78	$-0.67	$-0.55	$-0.57	$-0.48	$-0.61	$-0.56	$-0.69	$-0.65	$-0.71	$-0.28	$-0.59	$-0.26
Surprise %	-	-	-	-	-	-	-	-	-	0.85%	0.96%	0.89%	0.80%	0.98%	1.04%	1.26%	0.95%	1.00%	0.34%	1.04%	1.04%	0.97%	0.86%	4.21%	0.99%	1.64%

According to undefined Wall Street analysts, Protagonist Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PTGX previous annual EPS of $NaN (undefined).

Protagonist Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$2.37	$33.86	1328.69%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
ARVN	Arvinas	$19.10	$58.50	206.28%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
KURA	Kura Oncology	$9.74	$23.33	139.53%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
IDYA	IDEAYA Biosciences	$26.33	$53.33	102.54%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
MRUS	Merus	$44.90	$81.25	80.96%	Buy
RNA	Avidity Biosciences	$32.74	$59.00	80.21%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
REPL	Replimune Group	$11.72	$19.00	62.12%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
PTGX	Protagonist Therapeutics	$40.69	$57.33	40.89%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy
VRNA	Verona Pharma	$41.66	$39.50	-5.18%	Buy

PTGX Forecast FAQ

Is Protagonist Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Protagonist Therapeutics (PTGX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of PTGX's total ratings.

What is PTGX's price target?

Protagonist Therapeutics (PTGX) average price target is $57.33 with a range of $50 to $62, implying a 44.99% from its last price of $39.54. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Protagonist Therapeutics stock go up soon?

According to Wall Street analysts' prediction for PTGX stock, the company can go up by 44.99% (from the last price of $39.54 to the average price target of $57.33), up by 56.80% based on the highest stock price target, and up by 26.45% based on the lowest stock price target.

Can Protagonist Therapeutics stock reach $60?

PTGX's highest twelve months analyst stock price target of $62 supports the claim that Protagonist Therapeutics can reach $60 in the near future.

What is Protagonist Therapeutics's current price target trend?

2 Wall Street analysts forecast a $61 price target for Protagonist Therapeutics (PTGX) this month, up 54.27% from its last price of $39.54. Compared to the last 3 and 12 months, the average price target increased by 54.27% and increased by 32.78%, respectively.

What are Protagonist Therapeutics's analysts' financial forecasts?

Protagonist Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $318.22M (high $794.64M, low $21.5M), average EBITDA is $-78.669M (high $-23.356M, low $-154M), average net income is $-88.315M (high $844.97M, low $-716M), average SG&A $809.68M (high $1.83B, low $81.16M), and average EPS is $2.33 (high $24.12, low $-11.865). PTGX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $110.9M (high $282.25M, low $6.98M), average EBITDA is $-111M (high $-6.975M, low $-282M), average net income is $-88.843M (high $55.22M, low $-297M), average SG&A $1.59B (high $4.04B, low $99.85M), and average EPS is $-1.438 (high $0.894, low $-4.802).

Did the PTGX's actual financial results beat the analysts' financial forecasts?

Based on Protagonist Therapeutics's last annual report (Dec 2023), the company's revenue was $60M, which missed the average analysts forecast of $62M by -3.23%. Apple's EBITDA was $-93.652M, beating the average prediction of $-84.549M by 10.77%. The company's net income was $-78.955M, beating the average estimation of $-22.47M by 251.38%. Apple's SG&A was $33.49M, missing the average forecast of $887.53M by -96.23%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-0.673 by -99.79%. In terms of the last quarterly report (Jun 2022), Protagonist Therapeutics's revenue was $859K, beating the average analysts' forecast of $460K by 86.74%. The company's EBITDA was $-40.6M, beating the average prediction of $-460K by 8726.09%. Protagonist Therapeutics's net income was $-40.631M, missing the average estimation of $-57.339M by -29.14%. The company's SG&A was $7.69M, beating the average forecast of $6.58M by 16.80%. Lastly, the company's EPS was $-0.83, missing the average prediction of $-0.935 by -11.26%